Evidence map›Paper›PMID 41824151›Full record

ReviewMetabolic brain disease2026

Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review.

Laura Konczal, Gregory M Enns, Andrea L Gropman, Daniel Garcia, J Lawrence Merritt Ii, Greta Wilkening

Abstract readReview
In one paragraph

Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura KonczalUniversity Hospitals Cleveland Medical Center, 11100 Euclid Ave, Lakeside Ste 1500, Cleveland, OH, 44106, USA. laura.konczal@uhhospitals.org.
Gregory M EnnsDepartment of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, CA, USA.
Andrea L GropmanSt. Jude Children's Research Hospital, Memphis, TN, USA.
Daniel GarciaUltragenyx Pharmaceutical Inc, Novato, CA, USA.
J Lawrence Merritt IiUltragenyx Pharmaceutical Inc, Novato, CA, USA.
Greta WilkeningUniversity of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder associated with mild-to-severe neurological/cognitive symptoms that impact quality of life. Most patients are diagnosed with late-onset OTCD after 28 days of age. Emerging symptoms in adolescents and adults may not be recognized as effects of hyperammonemia, a common and potentially lethal complication of OTCD, and may contribute to substantial burden even when patients are diagnosed and treated. However, current reviews do not address this burden. Our aim is to raise awareness of neurological/cognitive manifestations of late-onset OTCD in adolescents and adults to reduce diagnostic delays and improve outcomes. Acutely, patients can present with signs of neurological impairment and psychiatric manifestations, which may be associated with a specific trigger or without known cause. Cognitive changes are more likely to be subacute or chronic, and onset may occur after hyperammonemia. As many late-onset OTCD cases are identified after presenting to emergency departments or primary care providers (often followed by hospital admission), education of frontline providers is needed to drive awareness, recognize symptoms, and improve patient care.

Indexed as

Cognition DisordersCognitive DysfunctionNervous System DiseasesOrnithine Carbamoyltransferase Deficiency DiseaseAdolescentAge of OnsetHumansHyperammonemiaCognitionHyperammonemiaNeurobehavioral manifestationsNeurologicalOrnithine transcarbamylase deficiency disease

Identifiers

PMID41824151
PMCPMC12987786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.